Gastric Adenocarcinoma in Young Patients: a Population-Based Appraisal
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although international studies of young gastric cancer patients have mainly reported favorable survival outcomes compared with older patients, US-based experiences have shown a wider spectrum of outcomes. We examined the impact of young age (under 45 years) on the presentation and survival outcomes of gastric adenocarcinoma.
A total of 33,236 patients with gastric adenocarcinoma were identified within the 1988–2006 Surveillance, Epidemiology, and End Results (SEER) registry. Multivariate regression analysis of relative survival was performed to adjust for covariate effects using generalized linear models.
Young patients were more likely than older patients to have advanced nodal and distant metastatic disease at presentation (P < 0.001 for both). Unadjusted relative survival analysis demonstrated younger patients to have favorable stage-stratified survival when compared with middle-aged and older patients. These findings persisted after adjusting for covariates. After stratifying for receipt of cancer-directed surgery, younger age was associated with more favorable stage-stratified relative survival.
This is the largest US population-based study of age-related gastric cancer outcomes. Although young patients with gastric cancer present with more advanced disease, their adjusted stage-stratified relative survival is more favorable than that of older patients. This study supports a stage-dependent treatment approach in younger populations.
- Gastric Adenocarcinoma in Young Patients: a Population-Based Appraisal
Annals of Surgical Oncology
Volume 18, Issue 10 , pp 2800-2807
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Surgical Oncology, Department of Surgery, University of Minnesota and Minneapolis Veteran Affairs Medical Center, Minneapolis, MN, USA
- 2. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA